<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02006264</url>
  </required_header>
  <id_info>
    <org_study_id>2013-329</org_study_id>
    <secondary_id>U19AI076980</secondary_id>
    <nct_id>NCT02006264</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring</brief_title>
  <acronym>TDF IVR-001</acronym>
  <official_title>Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, randomized, single-blinded, placebo controlled trial will examine the
      safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF)
      vaginal ring when used continuously for 14 consecutive days.

      The primary objective is to assess the safety of TDF vaginal rings when used continuously for
      14 days by healthy, HIV-uninfected, sexually abstinent women, as compared with a placebo
      vaginal ring.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tenofovir disoproxil fumarate (TDF) is a prodrug of TFV (tenofovir), an adenosine nucleoside
      monophosphonate (nucleotide) derivative with potent antiretroviral (ARV) activity. TDF
      permeates cells more rapidly than TFV resulting in increased intracellular accumulation of
      TFV-diphosphate (TFV-DP), the active metabolite. TDF is more potent than TFV and inhibits
      HIV-1 (Human Immunodeficiency Virus-1)and herpes simplex virus type 2 (HSV-2) infection in
      cell and tissue culture models at approximately 100-fold lower concentrations than TFV,
      suggesting that it may be an excellent candidate for prevention of HIV. TDF is licensed for
      the treatment of HIV-1 infection in the US, the European Union, Middle East, and Africa.

      The study will take place at the Albert Einstein College of Medicine in Bronx, New York, USA.
      Each participant will receive an IVR (intravaginal ring) containing TDF or a placebo ring.
      The vaginal ring will be worn continuously for 14 days. It will be inserted into the vagina
      following cessation of participant's menses, by the study clinician at Visit 3 and removed by
      the study clinician at Visit 7. Each participant will be followed for 7 days following ring
      removal.

      It is hypothesized that both the TDF IVR and placebo IVR will be safe and well tolerated
      among healthy, sexually abstinent women on combined-hormonal contraception. The null
      hypothesis is that there will be no difference in the safety profile between the active
      product and the placebo.

      Careful assessments of safety, including systemic and genital tract, will be undertaken with
      special consideration for issues related to irritation and systemic toxicity. The design of
      the study will allow safety comparisons of TDF ring to a placebo ring. A 14-day safety and PK
      study is proposed for this first-in-human study per FDA (For and Drug Administration)
      guidance. The study duration was carefully selected to control risk to the study
      participants. TFV 1% vaginal gel has been extensively tested in clinical trials at higher
      doses (8-fold dose margin) than the predicted dose delivered by the TDF IVR-001 study, and
      the TFV gel showed no significant adverse events at this higher dose in thousands of women.

      Given the drug release kinetics observed in vitro and in NHP (non-human primate) studies, TDF
      and TFV (formed following hydrolysis of the prodrug TDF) concentrations in cervicovaginal
      fluid (CVF) are expected to reach steady state within a few days and maintain steady state
      concentrations for the duration of the planned 14 days of ring use. Sampling at multiple time
      points and sites (vaginal, cervical, rectal and blood) will provide information on drug
      distribution, kinetics, and, by sampling after ring removal on Day 14, how long drug
      persists. The latter may be important as behavior studies suggest that some women may remove
      a ring at time of menses or around sex. To capture systemic absorption, blood will be sampled
      to determine drug concentrations in blood plasma and PBMCs (peripheral blood mononuclear
      cells). To capture the concentrations of drug within the genital tract, CVF will be sampled
      using Dacron swabs of the introitus, ectocervix, and area adjacent to the ring. Rectal
      sampling with swabs will also be obtained if participants consent to the procedure to
      determine drug concentrations in the rectum. Sampling at different sites (proximal and distal
      to the ring) will provide important information as to how well drug permeates throughout the
      genital tract. Cervical tissue sampling will be highly informative given that it is the
      likely site of drug action. However, biopsies must be taken sparingly for several reasons:
      they are uncomfortable to some and alter the healing process. Accordingly, two baseline
      biopsies will be taken prior to randomization and ring insertion to confirm absence of study
      drug and for PD studies. Subsequent biopsies for PK (pharmacokinetics) and PD
      (pharmacodynamics) studies will be delayed until the ring is removed. Following TDF IVR
      removal a third biopsy will be obtained for PK studies. Two cervical biopsies will be
      obtained following placebo IVR removal for PD studies and to blind safety data. The study
      will not be double-blinded because the TDF and placebo rings are not identical in appearance.
      Therefore, the study clinician will be able to collect two biopsies from participants in the
      placebo group and three biopsies from participants in the TDF ring group after ring removal.
      In order to maintain participant blinding, all participants will be informed that two
      biopsies will be taken before ring insertion and 2-3 biopsies will be taken after ring
      removal. Paired biopsies will provide the best data, as it will avoid inter-individual
      variability; both sets of cervical biopsies (pre- and post-IVR use) will be obtained during
      the second half of the participant's menstrual cycle (cycle days 18-23), which is prior to
      menses. Cervical biopsies will be obtained without local anesthetic. Participants may take
      acetaminophen before and/or after the biopsies are collected if desired.

      Primary Objective:

      • Assess the safety of TDF IVR when used continuously for 14 days by healthy, HIV-uninfected,
      sexually abstinent women, as compared with the placebo IVR

      Secondary Objective:

      • Examine systemic and genital tract PK of TDF release during and after 14 days of continuous
      use of a reservoir-type IVR containing TDF

      Exploratory Objectives:

        -  Evaluate the acceptability of and adherence to the study IVR

        -  Evaluate the PD during and after 14 days of continuous use of a reservoir-type IVR
           containing TDF by measuring the antiviral activity of genital tract secretions ex vivo
           and challenging biopsy tissue with virus

        -  Examine the impact of the study IVR on genital tract mucosal immunity and the vaginal
           microbiota

        -  Examine the PK of TDF and TFV in rectal fluid during and after 14 days of continuous use
           of a reservoir-type TDF IVR

        -  Evaluate mechanical properties and drug content following 14 days of continuous use of
           reservoir-type IVRs

      This is a single-site, two-arm, randomized single-blind, placebo-controlled trial. The study
      population will include approximately 30 healthy, 18-45 year old women who are
      HIV-uninfected, non-pregnant, sexually abstinent and using adequate contraception, as
      described in the protocol. This sample size was chosen with the goal of having 12 women per
      group complete the study and includes additional women to account for participants who may
      not complete the study or are lost to follow-up. Only female volunteers will be recruited
      since an IVR can only be used by women and the endpoints require genital sampling. To ensure
      participants are protected from pregnancy during study participation, to minimize variability
      among contraceptive methods, and to ensure adequate time between menses for ring use and
      sample collection, all volunteers must be using low-dose combined hormonal contraceptive
      pills. As this is a first-in-human trial of an intravaginal TDF ring, only healthy women will
      be recruited and will be asked to wear a TDF or placebo IVR for 14 days.

      The approximate time to complete study enrollment is expected to be 9 months. Two study
      groups are planned. Both groups will be assigned to complete a total of 9 study visits:
      (Screening [Visit 1], Enrollment [Visit 2], Days 0 [Visit 3], 1 [Visit 4], 3-5 [Visit 5], 7
      [Visit 6], 14 [Visit 7], 16-18 [Visit 8], 21 [visit 9]). A Safety Call will also be conducted
      on Day 10 of the study.

      The two study groups are:

        1. Reservoir-type TDF IVR group;

        2. Reservoir-type polyurethane IVR group;

      The expected duration for participants is approximately 5 - 10 weeks (including a screening
      visit, an enrollment visit, two weeks of continuous IVR use, and one week following IVR
      removal). Participants will undergo Visit 2 within 45 days of screening. No study data will
      be collected after the Final Study/Early Termination Visit unless the participant is pregnant
      at the Final Study/Early Termination Visit. Participants who have AEs (adverse events) at the
      Final Study/Early Termination Visit that have not resolved or stabilized will be followed
      beyond the Final Study/Early Termination Visit until a clinically acceptable resolution of
      the AE(s) is confirmed and documented. Clinical acceptability of resolution will be
      determined by the PL (Program Leader) in consultation with the Protocol Safety Review Team
      (PSRT). Participants who are pregnant at the Final Study/Early Termination Visit may be
      followed in accordance with procedures described in the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 19, 2013</start_date>
  <completion_date type="Actual">November 6, 2014</completion_date>
  <primary_completion_date type="Actual">November 6, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</measure>
    <time_frame>14 days of vaginal ring use</time_frame>
    <description>Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Grade 2 or Higher Adverse Events as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</measure>
    <time_frame>14 days of vaginal ring use</time_frame>
    <description>Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>TDF and TFV Maximum Concentrations (C-max) in CVF Genital Secretions (ECX and VAG) and TFV Maximum Concentration in Plasma</measure>
    <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
    <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDF and TFV Time to Maximum Concentrations (T-max) in CVF Genital Secretions (ECX and VAG), and TFV Time to Maximum Concentration in Plasma</measure>
    <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
    <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TDF AUC0-14 in CVF Genital Secretions (ECX and VAG), TFV AUC0-14 in CVF Genital Secretions (ECX and VAG), and TFV AUC0-14 in Plasma</measure>
    <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
    <description>TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TFV C-ave in Cervical Tissue</measure>
    <time_frame>before and after 14 days of vaginal ring use</time_frame>
    <description>TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TFV-DP C-ave in Cervical Tissue</measure>
    <time_frame>before and after 14 days of vaginal ring use</time_frame>
    <description>TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>TDF Intravaginal Ring</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir Disoproxil Fumarate intravaginal ring (TDF-IVR) is a white (with clear segment), flexible torus-shaped device with an inner core compartment comprised of TDF (86 wt% of formulation) and Sodium Chloride (NaCl) (14 wt% of formulation). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Intravaginal Ring</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo intravaginal ring (IVR) is a clear, flexible torus-shaped device with an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TDF Intravaginal Ring</intervention_name>
    <description>The TDF IVR intravaginal ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core compartment comprised of 86% w/w TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
    <arm_group_label>TDF Intravaginal Ring</arm_group_label>
    <other_name>TDF IVR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Intravaginal Ring</intervention_name>
    <description>The placebo ring is formulated using flexible outer tubing, comprised of hydrophilic, aliphatic polyether urethane, and an inner core comprised of sodium chloride (NaCl). The Placebo intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
    <arm_group_label>Placebo Intravaginal Ring</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  General good health (by volunteer history and per investigator discretion) without any
             clinically significant systemic disease (including, but not limited to significant
             liver disease/hepatitis, gastrointestinal disease, kidney disease, thyroid disease,
             osteoporosis or bone disease, and diabetes)

          -  Willing to give voluntary consent, sign an informed consent form and comply with study
             procedures as required by the protocol

          -  HIV-uninfected based on testing performed by study staff during screening procedures

          -  Using low dose combined (estrogen and progesterone-containing) oral contraceptive
             pills (does not include extended-cycle, 24 and 28-day active pill regimens). Per
             participant report must be using this contraceptive method with no change in the prior
             3 months and intending to use same method for the duration of study participation.

          -  Currently have a regular 28-day menstrual cycle on combined oral contraceptive pills.

          -  Normal Pap test at screening or appropriately documented history of Pap test and
             completed follow-up of any abnormal pap tests consistent with American Congress of
             Obstetricians and Gynecologists (ACOG) practice guidelines #99 and #109.

          -  Agrees not to participate in other research studies involving drugs, medical devices,
             or vaginal products for the duration of study participation.

          -  Able and willing to refrain from inserting any non-study vaginal products or objects
             into the vagina for the 48 hours prior to Visit 2 throughout the duration of the
             study.

          -  Able and willing to abstain from oral, vaginal and anal sex for 48 hours prior to
             Visit 2 throughout the duration of the study.

        Exclusion Criteria:

        Women must meet none of the following criteria prior to genital sampling at Visit 2:

          -  Known adverse reaction to polyurethane or to any components of the study product or
             allergy to both silver nitrate and Monsel's solution.

          -  Hepatitis B infection (defined as positive hepatitis B surface antigen).

          -  Chronic, recurrent, and/or acute vulvar or vaginal symptoms (pain, irritation,
             spotting, etc.).

          -  Known bleeding disorder that could lead to prolonged or continuous bleeding with
             biopsy.

          -  Pregnant or intending to become pregnant during the period of study participation.

          -  Currently breastfeeding or having breastfed an infant in the last two months, or
             planning to breastfeed during the course of the study.

          -  Menopause.

          -  History of unexplained or unresolved intermenstrual bleeding in the 3 months prior to
             screening.

          -  History of gynecological procedures (including genital piercing) on the external
             genitalia, vagina or cervix in the last 14 days.

          -  Hysterectomy.

          -  Use and/or anticipated use during the study period of an intravaginal or intrauterine
             device.

          -  Systemic use in the last 2 weeks or anticipated use during the study period of any of
             the following: corticosteroids, antibiotics, antifungals, antivirals, anticoagulants
             or antiretrovirals.

          -  Grade 1 or higher laboratory abnormality, per the August 2009 update of the Division
             of AIDS, National Institute of Allergy and Infectious Disease (DAIDS) Table for
             Grading the Severity of Adverse Events (AEs).

          -  In the last six months, diagnosed with or treated for any sexually transmitted
             infection (STI).

          -  Reproductive tract infection (RTI) or pelvic inflammatory disease (PID) requiring
             treatment per current CDC (Center for Disease Control and Prevention) guidelines at
             Screening or Enrollment.

          -  Positive test for Trichomonas vaginalis, Neisseria gonorrhea or Chlamydia trachomatis
             at screening.

          -  Reactive test for syphilis at screening.

          -  At Screening or Enrollment, has a clinically apparent Grade 1 or higher pelvic exam
             finding (observed by study clinician or designee) per the Division of AIDS Table for
             Grading the Severity of Adult and Pediatric Adverse Events, Addendum 1, Female Genital
             Grading Table for Use in Microbicide Studies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marla J Keller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, McNicholl JM, Hendry RM, Dinh CT, Martin A, Herold BC, Kiser PF. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16145-50. doi: 10.1073/pnas.1311355110. Epub 2013 Sep 16.</citation>
    <PMID>24043812</PMID>
  </reference>
  <reference>
    <citation>Mesquita PM, Rastogi R, Segarra TJ, Teller RS, Torres NM, Huber AM, Kiser PF, Herold BC. Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection. J Antimicrob Chemother. 2012 Jul;67(7):1730-8. doi: 10.1093/jac/dks097. Epub 2012 Mar 30.</citation>
    <PMID>22467632</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 19, 2013</study_first_submitted>
  <study_first_submitted_qc>December 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2013</study_first_posted>
  <results_first_submitted>April 17, 2018</results_first_submitted>
  <results_first_submitted_qc>July 30, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2018</results_first_posted>
  <last_update_submitted>July 30, 2018</last_update_submitted>
  <last_update_submitted_qc>July 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Marla Keller</investigator_full_name>
    <investigator_title>Prof. Dept of Medicine</investigator_title>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>TDF Intravaginal Ring</title>
          <description>TDF Intravaginal Ring (TDF-IVR)
The TDF (tenofovir disoproxil fumarate) IVR (intravaginal ring) has an inner core compartment comprised of 86% w/w (weight by weight) TDF and 14% w/w sodium chloride (NaCl). The TDF intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Intravaginal Ring</title>
          <description>Placebo Intravaginal Ring (Placebo IVR)
The placebo intravaginal ring (IVR) has an inner core which contains sodium chloride (NaCl). The intravaginal ring will be worn continuously for 14 days. It will be inserted into the vagina following cessation of participant's menses at Visit 3 and removed at Visit 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>TDF Intravaginal Ring</title>
          <description>TDF Intravaginal Ring (TDF IVR)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Intravaginal Ring</title>
          <description>Placebo Intravaginal Ring (Placebo IVR)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" spread="7.1"/>
                    <measurement group_id="B2" value="28.2" spread="5.7"/>
                    <measurement group_id="B3" value="29.65" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</title>
        <description>Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product</description>
        <time_frame>14 days of vaginal ring use</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 1 Genitourinary Events or Higher as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</title>
          <description>Grade 1 or higher Genitourinary events as defined by the DAIDS (Division of AIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period judged to be related to study product</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Grade 2 or Higher Adverse Events as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</title>
        <description>Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period</description>
        <time_frame>14 days of vaginal ring use</time_frame>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>Grade 2 or Higher Adverse Events as Defined by the DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events</title>
          <description>Grade 2 or higher systemic and local Adverse Events as defined by the Division of Aids (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events during the trial period</description>
          <units>Adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDF and TFV Maximum Concentrations (C-max) in CVF Genital Secretions (ECX and VAG) and TFV Maximum Concentration in Plasma</title>
        <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
        <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
        <population>TDF analytical data available for 14 of 15 participants for CVF VAG and CVF ECX. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>TDF and TFV Maximum Concentrations (C-max) in CVF Genital Secretions (ECX and VAG) and TFV Maximum Concentration in Plasma</title>
          <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) maximum concentrations (C-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)) and TFV maximum concentration (C-max) in plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
          <population>TDF analytical data available for 14 of 15 participants for CVF VAG and CVF ECX. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>C-max CVF VAG TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240000" lower_limit="140000" upper_limit="360000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-max CVF ECX TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210000" lower_limit="81000" upper_limit="320000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-max CVF VAG TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91000" lower_limit="73000" upper_limit="190000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-max CVF ECX TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85000" lower_limit="52000" upper_limit="170000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-max Plasma TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="1.2" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDF and TFV Time to Maximum Concentrations (T-max) in CVF Genital Secretions (ECX and VAG), and TFV Time to Maximum Concentration in Plasma</title>
        <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
        <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
        <population>TDF analytical data available for 14 of 15 participants for CVF VAG and CVF ECX. TFV analytical data available for 12 of 15 participants for Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>TDF and TFV Time to Maximum Concentrations (T-max) in CVF Genital Secretions (ECX and VAG), and TFV Time to Maximum Concentration in Plasma</title>
          <description>TDF (tenofovir disoproxil fumarate) and TFV (tenofovir) time to maximum concentrations (T-max) in CVF (Cervicovaginal Fluid) genital secretions (ectocervix (ECX) and vagina (VAG)), and TFV time to maximum concentration in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
          <population>TDF analytical data available for 14 of 15 participants for CVF VAG and CVF ECX. TFV analytical data available for 12 of 15 participants for Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>T-max CVF VAG TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="3" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-max CVF ECX TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="4" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-max CVF VAG TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-max CVF ECX TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="3" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-max Plasma TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="14" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TDF AUC0-14 in CVF Genital Secretions (ECX and VAG), TFV AUC0-14 in CVF Genital Secretions (ECX and VAG), and TFV AUC0-14 in Plasma</title>
        <description>TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
        <time_frame>1, 3, 7 and 14 days after ring insertion and 2 and 7 days after ring removal</time_frame>
        <population>TDF analytical data available for 13 of 15 participants for CVF ECX, and 14 of 15 participants for CVF VAG. TFV analytical data available for 13 of 15 participants for CVF ECX. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>TDF AUC0-14 in CVF Genital Secretions (ECX and VAG), TFV AUC0-14 in CVF Genital Secretions (ECX and VAG), and TFV AUC0-14 in Plasma</title>
          <description>TDF (tenofovir disoproxil fumarate) AUC0-14 (Area Under the Curve (concentration versus time) days 0-14) in Cervicovaginal Fluid (CVF) genital secretions (ectocervix (ECX) and vagina(VAG)), TFV AUC0-14 in CVF genital secretions (ECX and VAG), and TFV (tenofovir) AUC0-14 in Plasma. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
          <population>TDF analytical data available for 13 of 15 participants for CVF ECX, and 14 of 15 participants for CVF VAG. TFV analytical data available for 13 of 15 participants for CVF ECX. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
          <units>ngxd/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC0-14 (days 0-14), CVF VAG TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2000000" lower_limit="690000" upper_limit="3200000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-14 (days 0-14), CVF ECX TDF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1300000" lower_limit="340000" upper_limit="2100000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-14 (days 0-14), CVF VAG TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1100000" lower_limit="670000" upper_limit="2100000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-14 (days 0-14), CVF ECX TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="970000" lower_limit="570000" upper_limit="1300000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC0-14 (days 0-14), Plasma TFV</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" lower_limit="6.9" upper_limit="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TFV C-ave in Cervical Tissue</title>
        <description>TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
        <time_frame>before and after 14 days of vaginal ring use</time_frame>
        <population>PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>TFV C-ave in Cervical Tissue</title>
          <description>TFV (tenofovir) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
          <population>PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
          <units>ng/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" lower_limit="2.8" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TFV-DP C-ave in Cervical Tissue</title>
        <description>TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
        <time_frame>before and after 14 days of vaginal ring use</time_frame>
        <population>PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>TDF Intravaginal Ring</title>
            <description>TDF Intravaginal Ring (TDF IVR)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Intravaginal Ring</title>
            <description>Placebo Intravaginal Ring (Placebo IVR)</description>
          </group>
        </group_list>
        <measure>
          <title>TFV-DP C-ave in Cervical Tissue</title>
          <description>TFV-DP (tenofovir diphosphate) average concentration (C-ave) in cervical tissue. PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</description>
          <population>PK parameters only measured in TDF IVR subjects, not Placebo IVR subjects.</population>
          <units>fmol/mg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120" lower_limit="90" upper_limit="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>TDF Intravaginal Ring</title>
          <description>TDF Intravaginal Ring (TDF IVR)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Intravaginal Ring</title>
          <description>Placebo Intravaginal Ring (Placebo IVR)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marla Keller, MD, Principal Investigator</name_or_title>
      <organization>Albert Einstein College of Medicine</organization>
      <phone>718-430-3240</phone>
      <email>marla.keller@einstein.yu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

